What service do you need? Contact Request

NCT06365879

To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria

← Clinical trials hub

Registry fields

Overall status: COMPLETED
Conditions: Chronic Spontaneous Urticaria
Study type: INTERVENTIONAL
Phase: PHASE3
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: CMAB007, Xolair
Lead sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd (INDUSTRY)

Cached at: 2026-10-03 08:59:58

View on ClinicalTrials.gov

Brief summary

This study is a multicenter, randomized, double-blind, positive parallel controlled phase III clinical trial to compare efficacy, immunogenicity, pharmacokinetics, pharmacodynamics and safety of omalizumab α(CMAB007) and Xolair® in patients with refractory chronic spontaneous urticaria

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report

Contact Support